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Summary: An evaluation of the Bayer-Technicon Chem-1 multitest analyzer is described over the period
1989 — 1992. Various aspects like daily use, running costs and quality assessment are discussed. The whole
process regarding the performance, ranging from negative feelings in the first year to satisfaction in the third,
is followed critically.
Introduction
In 1988 we initiated a complete reorganization of the
routine chemistry division of our laboratory. The
most important reasons for this were economics, tech-
nical aging of the existing equipment and the need
for cost containment, as well as streamlining of the
sample handling procedures.
The existing equipment consisted of a Technicon
SMAC for electrolytes and substrates and LKB re-
action-rate analyzers for enzymes, together with a
DuPont ACA III for emergencies 24 h a day and a
Technicon RA-1000 for back-up.
Basic requirements were:
1. A test capacity during office hours of at least
5000-6000 tests per day.
2. Two or three identical instruments for the whole
routine test panel.
3. Emergency testing on the same instrumentation 24
hours per day.
4. Reporting time of about 30 minutes after admit-
tance of the sample.
5. Acceptable and competitive price for the running
costs.
In addition to these requirements we took into con-
sideration: precision and accuracy aspects, technical
aspects including computer facilities, reputation of
the instrument and/or manufacturer, acceptability to
the personnel and environmental aspects regarding
the reagents.
After lengthy discussions with manufacturers as well
— understandable because we are one of the largest
hospital laboratories in The Netherlands — we chose
the Technicon Chem-1. We were aware of the risk we
were taking. As is known, the instrument was
launched in 1985 in Paris with enthusiasm and success,
but subsequently given up afterwards in a number of
places. We finally arrived at an acceptable agreement
with Bayer-Technicon, which was also based on a
long-lasting relationship.
An important part of this agreement, an extensive
testing of the performance of the instrument, has
already been described earlier (1). This evaluation led
to a positive decision regarding the purchase of two
instruments with revised software. Earlier instruments
had been introduced and were not accepted in other
Dutch laboratories. In October 1989 our instruments
were installed in the laboratory for use during office
hours by 9 well-trained technicians, while in March
1990 all routine (20 chemistries) and most of the
emergency tests were run at night and during the
weekends as well by 40 technicians in rotating shifts.
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Consideration 1990
By the end of the year 1990 it was clear that our
work-flow had improved considerably compared to
the earlier situation. It was also clear that our work
with both Chem-l's required much more effort some-
times than we considered acceptable and at a rather
high price. We therefore decided to start a pilot study
and agreed with Bayer-Technicon to discuss our ex-
perience.
The pilot study focussed on three main items:
1. Daily use of the instruments
2. Running costs
3. Quality assessment of the results
Ad 1
The main problems we met in the first year were
stability, tqqhnical and reagent problems. Most of the
stability problems were detected by our internal qual-
ity control system based on the Westgard rules (2),
which was implemented on our local area network.
The other problems were mostly clear because they
were due to system or cassette malfunction.
All problems led to a waste of time because we had
to recalibrate and/or restart.
Because all these problems were ad hoc we wanted,
in addition to keeping the manufacturer's mainte-
nance log book, to get a more detailed picture of the
entire analytical process. We therefore introduced an
internal log book for one month (November 1990),
documenting every hitch and problem, the causes, the
actions taken and the time delay.
Out of the 20 working days we observed only 3 passed
without any problem, 10 had minor problems (delay
less than 30 minutes) and 7 had more serious problems
although we needed the help or advice of a Bayer-
Technicon service engineer only 3 times. In all situa-
tions we encountered no delay in reporting to the
wards.
Over the year 1990 we had contact with the Bayer-
Technicon service department, by phone or in person,
every two weeks on an average.
We paid special attention to the handling of emer-
gency specimens 24 hours a day. In our earlier report
we already mentioned our concern regarding the lim-
ited facility of the Chem-1 for processing these spec-
imens. During office hours we analyze about 100 stat
specimens.
In a separate study, lasting 10 days, we found a mean
reporting time of 57 minutes after admittance of the
sample, with a range of 31 to 85 minutes.
For the night shift the situation was different. Though
all technicians were well-trained, the level of experi-
ence from person to person was different. This some-
times resulted in uncertainty, leading to more control
measurements and/or recalibrations than were strictly
necessary, which meant delays in reporting.
Ad 2
The offer Bayer-Technicon made regarding the run-
ning costs of the Chem-1 was favourable in compar-
ison with other manufacturers, satisfying one of our
basic requirements. On the basis of our experience in
the first year it seemed without doubt that the price
per test was higher than had been predicted. We tried
two methods to gain insight into the average test price
for the year 1990. Our hospital information system
gave us the total number of reported patient requests
and the counters on the systems informed us of the
total number of tests. These data proved to differ by
about 50%, with patient requests being the lower, of
course.
Evaluating all the reasons for our loss of reageints,
with time-out errors of the cassettes being the most
important ones, we were able to explain 30% of this
difference. The remaining 20% were difficult to trace.
It should be mentioned here that the test price cal-
culated from the counter numbers of the systems
agreed well with the offer Bayer-Technicon made
based on our test pattern information.
Ad 3
In the internal log book mentioned in Section 1 we
also noted down the reason why a sample had to be
rerun for one or more requests. One reason might be
technical (instrument or cassette), another some vio-
lation of our quality control rules. We also checked
how many times the first result of an analysis had to
be changed.
During November 1990 4.3% of the estimations had
to be repeated, 2.0% because of technical reasons and
2.3% because of quality control reasons. The majority
of these reruns were caused by creatinine and chloride,
and to a lesser extent by sodium, potassium, calcium*
magtiesium, γ-glutamyltransferase and alanine ami-
notransferase assays. In only a very few eases did the
first result have to be corrected, except for chloride.
The figures were: 235 results out of 106992 had to be
corrected, 165 χ chloride, 17 χ creatinine, 12 χ
calcium, 12 χ alanine aminotransferase, 19 χ sodium
and some other determinations only incidentally.
In nearly all situations, except where we met a cassette
time-out or an instrumental failure, we were able to
resolve all problems by recalibration.
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The external quality assessment as organized by the
Dutch Quality Assessment Foundation was a reflec-
tion of our internal pattern: poor chloride and cre-
atinine methods and sometimes warnings for sodium,
potassium, calcium and γ-glutamyltransferase.
Conclusion 1990
At the end of 1990 we were balancing between giving
up the systems and continuating to face the challenge.
A first conclusion was that we had invested too much
time and effort in our chemistry section. It was also
clear, on the other hand, that we could work with
both Chem-l's. From October 1989 to December
1990 we never lost control over reporting the daily
routine on time.
This was in contrast with earlier experience in other
Dutch laboratories, and it led to a reconfirmation of
our earlier evaluation. On the other hand, it had only
been possible to obtain this result thanks to the skill
and dedication of our technical staff and the compe-
tence of the Bayer-Technicon service department.
Constructive discussions with Bayer-Technicon fol-
lowed, which resulted in a decision to continue. We
also decided to separate the handling of all emergency
tests from the routine workload. This change was
accomplished by June 1991. It meant a gain in re-
porting time of nearly half an hour.
Consideration 1992
Early in 1992 we felt the need to evaluate the whole
operation again. This time for positive reasons, be-
cause we had seen a considerable improvement in our
daily practice as compared with 1990. Since the intro-
duction of our instruments several changes had been
implemented, i. e. two software updates and a modi-
fied chloride formulation, the technicians had gained
more experience and they experienced less pressure in
the laboratory because stat tests had been rerouted.
In order to assess this improvement objectively we
considered the same aspects as described before. Once
again an extensive internal log book was introduced,
for the month of March 1992 and other general in-
formation was documented.
Using the same criteria as in November 1990 in the
20 days of evaluation we registered 10 without any
problem, 9 with a minor delay and 1 with a delay of
60 minutes. There was no need for a service contact
with Bayer-Technicon. The delays we had in this
period were known to us, although we did not see
them often: synchronization failure, transportation
problem or quality control warning.
Over the year 1992 the service calls or visits were
diminished by 50%.
Looking at the running costs we also got a clearer
picture. Taking into account all reagents and consum-
able costs we calculated an average test price that
differed less than 10% from the one Bayer-Technicon
had offered. During the March 1992 period we re-
corded that 2.8% of the estimations had to be re-
peated, 1.6% for technical and 1.2% for quality con-
trol reasons. This showed a considerable improvement
in comparison with the previous period. No such
outliers as found before were seen. We performed a
total of 93188 estimations in the 20 days. Only inci-
dentally, much less than in November 1990, did a first
result have to be corrected.
Additional study
Recently a Working Group of the European Group
for the Evaluation of Reagents and Analytical Sys-
tems in Laboratory Medicine published quality spec-
ifications for the imprecision and inaccuracy of ana-
lytical systems (3). It seemed to us worthwhile to
compare the imprecision data of this Working Group
with our earlier data, the results of a recent survey
and the specifications of Bayer-Technicon.
In summary the results of a recent survey show that
our Chem-l's perform less well than the quality spec-
ification of the working group expected for creatinine,
sodium, chloride, calcium, magnesium, total protein
and albumin. It is interesting to note that our earlier
experience shows a better performance for creatinine,
total protein and albumin. The specifications of the
manufacturer are all fullfilled. We will report on this
study more extensively later on.
Discussion
To our knowledge there is no report in the literature
on a longitudinal evaluation study like ours. This is
understandable because its practical value is limited.
However, we felt the need to describe our experience,
as never before had a new installation demanded so
much attention from us in contrast with our expec-
tations. It is clear that both we and the manufacturer
have succeeded.
It was not our intention to approach mathematical
exactness in our evaluation report and in the descrip-
tion of the various aspects we considered. In addition,
we had never planned to do a study like the one
described. Comparing the first year with the third we
feel that we are now running reliable equipment.
Eur. J. Clin. Chem. Clin. Biochem. / Vol. 31,1993 / No. 11
790 Blijenberg et al.: Performance of the Chem-1 revisited
Despite this positive judgement one can ask what
changes contributed most to this improvement. In our
opinion there are four primary reasons.
1. As we mentioned, we started with a well-trained
staff. Nevertheless, the organizational change in
our laboratory, combined with the implementation
of a completely new quality control system caused
a dramatic change in attitude. It is thus under-
standable that the third year looks better than the
first because of the increase in experience.
2. Technically, there were considerable improve-
ments: newer software versions, better cassettes
(drop in time-out errors by 50%) and newer meth-
ods (e. g. for chloride).
3. We removed the emergency work from the systems,
which reduced a lot of the tension in the sample
handling. Nonetheless, the total workload in both
years proved to be about the same.
4. Last but not least: we work with two analyzers,
which means that in reality a delay is never truly
a delay except in extreme situations (which occur
seldomly). The question arises, of course, as to
whether a stand-alone situation is attractive or not.
We have no experience here, because it would have
contradicted an important basic requirement we
set ourselves at the outset. However, we can un-
derstand some hesitation then, although this holds
true for every choice.
It might seem that we have no further critical remarks.
This is not true. We may be stringent with regard to
our quality control discipline but we prefer to rerun
less than we really do as described before. It is difficult
to compare our situation with that of other labora-
tories with comparable and competitive analyzers. We
are aware that we have encountered problems that
occur with other manufacturers as well (recall of
reagents, adjustment of a calibrator value, etc.), as
has been our experience.
We also feel that method improvement has not been
given enough attention in the Bayer-Technicon com-
pany in relation to the Chem-1. There is a need for
improvement of a number of methods. The determi-
nation of creatinine (4), sodium, potassium, chloride
and calcium still demand a lot of our attention.
Finally, the question arises as to what we learned
from the whole period. We feel that our choice of two
Chem-1 systems was correct, although it took some
time to arrive at this conviction. In a technical sense
we were well supported by Bayer-Technicon. On the
other hand, as we are still the only Dutch Chem-1
customer, we also sometimes feel lonely as regards
support from other laboratories. The information
flow from the manufacturer is meagre.
The Chem-1 was introduced too early. It is still a
highly sophisticated analyzer. TJhe implementation in
our laboratory proved to be a good example of co-
operation between a manufacturer well established in
the field of clinical chemistry and the dedication and
skill of our technical staff. There are no reasons not
to include Bayer-Technicon in discussions relating the
any replacement of our analyzers in the future.
Acknowledgements
The whole evaluation would not have been possible without
the help of: L. J. Perret, C. J. van Leeuwen, R. Leeneman, L.
T. Freimann, H. A. Roetering and G. C. Verheij.
Thanks are also due to Dr. G. /. M. Boerma and Dr. J.
Lindemans for reading the manuscript and to A. P. Copper-
Staamer for clerical assistance.
The Manufacturer's Response
We thank the authors for the constructive and critical
work they described in this evaluation report. We are
pleased with this report which we recognize as a
reward of all Miles-Technicon employees who worked
on the Chem-1 project for several years to improve
the reliability of the Chem-1 system.
The comments we have are the following:
1. More graphics would have enhanced the report.
For instance by mentioning the number of service
interventions between 1990,1991 and 1992 and the
number of reruns during the same period. And
also by subdividing the service intervention in time
(< 30 minutes, ± 2 hours and > 1 day) and kind
of repair (operator or service engineer).
2. A more detailed cost calculation for reportable
results is needed in order to get a clearer picture.
3. From the additional comparison study it is clear
(in words) that out 20 tests the Chem-1 performs
well for at least 13 tests (last survey comparison)
or 16 tests (original data comparison). The speci-
fications of the Working Group (3) are in our
opinion too tight regarding sodium, chloride and
calcium for every manufacturer unless they are
willing to spend a lot of time and money for
improvement.
4. A person who is not familiar with the system has
difficulties to understand the technical terms i. e.
synchronization failure, transport problem and QC
warning. We recommend to explain this in more
detail.
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